Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Entry point for public reimbursement Using the reduced off-patent price as a strong argument for increased access, Canada could become the first market with wide-scale reimbursement of existing primary care medicines, including GLP-1s for diabetes, to designate off-patent semaglutide as the first-line anti-obesity medication (AOM)
TrimRx partners exclusively with FDA-registered 503B facilities to ensure safety and quality
Obesity is not only an aesthetic concern but a complex medical condition associated with type 2 diabetes, cardiovascular disease, hypertension, cancer, and reduced life expectancy
Each vial is freeze-dried in-house using our proprietary lyophilization technique designed to preserve peptide integrity through cold and heat cycles during shipping and storage for up to 30 days before refrigeration becomes necessary
